Ashutosh Lal, MD

Prof of Clinical Pediatrics
M_PEDS-HEMATOLOGY

Ashutosh Lal, MD, is a hematologist at University of California San Francisco Benioff Children’s Hospital Oakland, Professor of Pediatrics, UCSF School of Medicine, Director of Clinical Hematology, Comprehensive Thalassemia Center and Iron Disorders Program, and the Hemoglobinopathy Diagnostics Laboratory. His academic and clinical interests are the treatment and research in thalassemia, iron overload, and nutrition. The Comprehensive Thalassemia Program in Oakland is the largest clinical program in the country actively managing 350 active patients with thalassemia. Dr. Lal conducts research in the epidemiology and natural history of thalassemia, molecular diagnostics, iron quantification, micronutrient deficiencies, iron chelation, and the development of new therapies for beta thalassemia. He is the principal investigator of the Thalassemia Western Consortium which is  supported through federal grants to improve the access to specialized care for patients with thalassemia living throughout the western United States.Ashutosh Lal, MD, is a hematologist at University of California San Francisco Benioff Children’s Hospital Oakland, Professor of Pediatrics, UCSF School of Medicine, Director of Clinical Hematology, Comprehensive Thalassemia Center and Iron Disorders Program, and the Hemoglobinopathy Diagnostics Laboratory. His academic and clinical interests are the treatment and research in thalassemia, iron overload, and nutrition. The Comprehensive Thalassemia Program in Oakland is the largest clinical program in the country actively managing 350 active patients with thalassemia. Dr. Lal conducts research in the epidemiology and natural history of thalassemia, molecular diagnostics, iron quantification, micronutrient deficiencies, iron chelation, and the development of new therapies for beta thalassemia. He is the principal investigator of the Thalassemia Western Consortium which is  supported through federal grants to improve the access to specialized care for patients with thalassemia living throughout the western United States.

Publications

Betibeglogene Autotemcel (Beti-cel) Gene Addition Therapy Results in Durable Hemoglobin A (HbA) Production with up to 10 Years of Follow-up in Participants with Transfusion-Dependent ß-Thalassemia.

Transplantation and Cellular Therapy

Timothy S. Olson, Alexis A. Thompson, Janet L. Kwiatkowski, Jennifer Schneiderman, Isabelle Thuret, Andreas E. Kulozik, Evangelia Yannaki, Marina Cavazzana, Suradej Hongeng, Martin G. Sauer, Adrian J. Thrasher, Ashutosh Lal, John E.J. Rasko, Hancheng Jiang, Ge Tao, Himal L. Thakar, Niki Witthuhn, Mark C. Walters, Franco Locatelli

Betibeglogene Autotemcel (beti-cel) Gene Addition Therapy Results in Durable Hemoglobin a Production with up to 10 Years of Follow-up with Transfusion-Dependent ß-Thalassemia.

Blood

Alexis Thompson, Janet L. Kwiatkowski, Jennifer Schneiderman, Isabelle Thuret, Andreas E. Kulozik, Evangelia Yannaki, Marina Cavazzana, Suradej Hongeng, Timothy S. Olson, Martin G. Sauer, Adrian J. Thrasher, Ashutosh Lal, John E. J. Rasko, Shamshad Ali, Ge Tao, Himal L. Thakar, Ami Deora, Clark Paramore, Niki Witthuhn, Mark C. Walters, Franco Locatelli

Sustained Efficacy and Safety in Adult and Pediatric Patients with Transfusion-Dependent ß-Thalassemia up to 9 Years Post Treatment with Betibeglogene Autotemcel (Beti-cel).

Transplantation and Cellular Therapy

Mark C. Walters, Alexis A. Thompson, Timothy S. Olson, John B. Porter, Jennifer Schneiderman, Suradej Hongeng, Andreas E. Kulozik, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, John E.J. Rasko, Evangelia Yannaki, Shamshad Ali, Ge Tao, Himal L. Thakar, Ami Deora, Katiana Gruppioni, Richard A. Colvin, Franco Locatelli, Janet L. Kwiatkowski

Improvement in Iron Burden in Patients with Transfusion-Dependent ß-Thalassemia (TDT) Treated with Betibeglogene Autotemcel (Beti-cel) Gene Therapy: Up to 9 Years of Follow-up.

Blood

Janet L. Kwiatkowski, Timothy S. Olson, Mark C. Walters, John B. Porter, Jennifer Schneiderman, Suradej Hongeng, Andreas Kulozik, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, John E. J. Rasko, Evangelia Yannaki, Shamshad Ali, Gloria Tao, Ami Deora, Himal L. Thakar, Richard A. Colvin, Franco Locatelli, Alexis A. Thompson

Sustained Efficacy, Safety, and Improved Quality of Life in Adult and Pediatric Patients with Transfusion-Dependent ß-Thalassemia up to 9 Years Post Treatment with Betibeglogene Autotemcel (Beti-cel).

Blood

Alexis A. Thompson, Timothy S. Olson, Mark C. Walters, John B. Porter, Jennifer Schneiderman, Suradej Hongeng, Andreas Kulozik, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, John E. J. Rasko, Evangelia Yannaki, Shamshad Ali, Gloria Tao, Himal L. Thakar, Ami Deora, Katiana Gruppioni, Richard A. Colvin, Franco Locatelli, Janet L. Kwiatkowski

385 Long-term Outcomes of 63 Patients with Transfusion-Dependent ß-Thalassemia (TDT) Followed-up to 7 Years after Treatment with betibeglogene autotemcel (beti-cel) Gene Therapy (GT) and Factors Impacting Neutrophil and Platelet Engraftment.

Transplantation and Cellular Therapy

Timothy S. Olson, Mark C. Walters, Janet L. Kwiatkowski, John B. Porter, Jennifer Schneiderman, Suradej Hongeng, Andreas E. Kulozik, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, John E.J. Rasko, Evangelia Yannaki, Shamshad Ali, Richard A. Colvin, Franco Locatelli, Alexis A. Thompson

Long Term Outcomes of 63 Patients with Transfusion-Dependent ß-Thalassemia (TDT) Followed up to 7 Years Post-Treatment with betibeglogene autotemcel (beti-cel) Gene Therapy and Exploratory Analysis of Predictors of Successful Treatment Outcomes in Phase

Blood

Mark C. Walters, Janet L. Kwiatkowski, John B. Porter, Jennifer Schneiderman, Suradej Hongeng, Andreas E. Kulozik, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, John E.J. Rasko, Evangelia Yannaki, Shamshad Ali, Ilya Shestopalov, Maeva Fincker, Richard A. Colvin, Dustin Whitney, Franco Locatelli, Alexis A. Thompson

28 Efficacy and Safety of Betibeglogene Autotemcel (beti-cel) Gene Therapy in 63 Patients with Transfusion-Dependent ß-Thalassemia (TDT): 7-Year Post-Infusion Follow-up of Phase 1/2 and Phase 3 Studies.

Transplantation and Cellular Therapy

Jennifer Schneiderman, Franco Locatelli, Alexis A. Thompson, Janet L. Kwiatkowski, John B. Porter, Suradej Hongeng, Andreas E. Kulozik, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, John E.J. Rasko, Evangelia Yannaki, Manfred Schmidt, Lin Du, Richard A. Colvin, Mark C. Walters

1 Efficacy and Safety of Betibeglogene Autotemcel (beti-cel; LentiGlobin for ß-thalassemia) Gene Therapy in 60 Patients with Transfusion-Dependent ß-Thalassemia (TDT) Followed for up to 6 Years Post-Infusion.

Suradej Hongeng, Alexis A. Thompson, Janet L. Kwiatkowski, Franco Locatelli, John B. Porter, John Rasko, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, Andreas E. Kulozik, Evangelia Yannaki, Manfred Schmidt, Ying Chen, Ruiting Guo, Weijian Liu, Richard A. Colvin, Mark C. Walters

122 Safety and Efficacy Outcomes in Pediatric Patients with Transfusion-Dependent ß-Thalassemia (TDT) Receiving Betibeglogene Autotemcel (beti-cel; LentiGlobin for ß-thalassemia) Gene Therapy in the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3

Mark C. Walters, Janet L. Kwiatkowski, John B. Porter, Suradej Hongeng, Evangelia Yannaki, Andreas E. Kulozik, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, Ruiting Guo, Weijian Liu, Richard A. Colvin, Franco Locatelli, Alexis A. Thompson

Response of Patients with Transfusion-Dependent ß-Thalassemia (TDT) to Betibeglogene Autotemcel (beti-cel; LentiGlobin for ß-Thalassemia) Gene Therapy Based on HBB Genotype and Disease Genetic Modifiers.

Blood

Mark C. Walters, David H.K. Chui, John J Farrell, Ashutosh Lal, Franco Locatelli, Janet L. Kwiatkowski, John B. Porter, Martin G. Sauer, Isabelle Thuret, Suradej Hongeng, Andreas E. Kulozik, Adrian J. Thrasher, Evangelia Yannaki, Julia Yang, Dustin Whitney, Alexandria Petrusich, Richard A. Colvin, Alexis A. Thompson

A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent �-Thalassemia.

The New England journal of medicine

Cappellini MD, Viprakasit V, Taher AT, Georgiev P, Kuo KHM, Coates T, Voskaridou E, Liew HK, Pazgal-Kobrowski I, Forni GL, Perrotta S, Khelif A, Lal A, Kattamis A, Vlachaki E, Origa R, Aydinok Y, Bejaoui M, Ho PJ, Chew LP, Bee PC, Lim SM, Lu MY, Tantiworawit A, Ganeva P, Gercheva L, Shah F, Neufeld EJ, Thompson A, Laadem A, Shetty JK, Zou J, Zhang J, Miteva D, Zinger T, Linde PG, Sherman ML, Hermine O, Porter J, Piga A, BELIEVE Investigators

Interim Results from the Phase 3 Hgb-207 (Northstar-2) and Hgb-212 (Northstar-3) Studies of Betibeglogene Autotemcel Gene Therapy (LentiGlobin) for the Treatment of Transfusion-Dependent ß-Thalassemia.

Biology of Blood and Marrow Transplantation

Jennifer Schneiderman, Alexis A. Thompson, Mark C. Walters, Janet L. Kwiatkowski, Andreas E. Kulozik, Martin G. Sauer, John B. Porter, Isabelle Thuret, Suradej Hongeng, Ashutosh Lal, Adrian J. Thrasher, Evangelia Yannaki, Heidi Elliot, Ge Tao, Weijian Liu, Richard A. Colvin, Franco Locatelli

Role